RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid TumorsI forgot to say who I sent it to. It was GSC. Some staff have in the research group have been made aware of 1902 by me over the past year but without them having any concrete, they do not know what is really up.
Mannequin wrote: I am aware that of some staff in the oncology group in the UK are attending the upcoming ASCO sessions. I've passed along the latest release. However unless the management has personally tried to reach out, then they will be sitting waiting for someone to show up.
The company really needs to be say more, explain more and get out there.
SPCEO1 wrote: Unfortunately, the leadership team has burned through nearly all of their credibility. So, while there was good news in that press release, few are even reading it and fewer still are going to react to it. THTX needs to announce something that has real dollars attached to it (like a partnership for TH-1902) to get investors to take a look at what they are doing. It sounds like anything like that, if it is going to happen, will be in the fourth quarter of this year. But the press release does increase hope that something favorable may occur in Part 3 of their phase 1 trial. And good data/good partnerships will attract a lot of attention to THTX's stock, even if the market does not fully trust management. But they have to get to that good data first to get a good partnership. They can announce anything about the part 3 trial anytime they want, so maybe we could get some preliminary good info, if it exists, before the fourth quarter.
Hopefully, this info convinces large shareholders to continue to hold onto their shares until the final word on the part 3 trial is out. The big risk now is that Soleus or other large shareholders start selling their shares into the current ultra-thin market for THTX.
The other big risk is that sales do not recover much from the first quarter crash. I suspect they will recover but making their guidance number after such a poor start to the year will be a big challenge.
ANALIAS00 wrote: Nobody seems to care !! That is weird.